UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk - Benzinga

Goldman Sachs initiates its coverage on Acorda Therapeutics (NASDAQ: ACOR) with a Sell rating and a price target of $21. Goldman Sachs says, "We view the US market for its key asset Ampyra as largely defined and do not see room for upside to consensus ...

New drug gives Islamorada MS patient freedom of movement - KeysNet

Drug offers new hope In 2010, the Food and Drug Administration approved a new drug made by Acorda Therapeutics based in Hawthorne, N.Y. Ampyra is an extended-release tablet designed to help MS patients with their walking. Meulenberg told her ...

Goldman Sachs Initiates Coverage on Acorda Therapeutics (ACOR) - zolmax.com

The firm set a “sell” rating on the stock. The analysts wrote, “We view the US market for its key asset Ampyra as largely defined and do not see room for upside to consensus estimates, which we would consider necessary to take shares higher.

Goldman Sachs Starts Acorda Therapeutics, Inc. (ACOR) at Sell - StreetInsider.com

The firm said the US market for Ampyra as largely defined and they do not see room for upside to consensus estimates which would be necessary to boost shares. Goldman also said the consensus is underestimating expenses, which could hit the stock.

Acorda Therapeutics Inc. Reports Operating Results (10-Q) - GuruFocus

The cost of Ampyra inventory is based on a percentage of net product sales of the product in the quarter shipped to Acorda by Alkermes or our alternative manufacturer. In a quarter when there is a price increase, such as the three-month period ended March ...

Alkermes biotech group doubles revenues for year to end March - Irish Times

It also makes type-2 diabetes therapy Bydureon, Vivitrol for the treatment of alcohol dependence and opiate relapse prevention and Ampyra, which helps improve walking in multiple sclerosis patients.

Revenues Skyrocket at Merged Alkermes - Yahoo Finance

These schizophrenia drugs are marketed by Johnson & Johnson (JNJ). Alkermes recorded manufacturing and royalty revenues from Ampyra/Fampyra, marketed for improving walking ability in multiple sclerosis patients, were $13.8 million in the reported quarter.

6 High-Growth Mid Caps Rated As Buy Or Better - Seekingalpha.com

It manufactures and commercializes VIVITROL for alcohol and opioid dependence; RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA to improve walking in patients with multiple sclerosis ...

Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - PharmiWeb

Manufacturing and royalty revenues from AMPYRA®/FAMPYRA®1 were $24.6 million for fiscal 2012. Alkermes, Inc. did not record any revenues for AMPYRA/FAMPYRA for fiscal 2011. Net sales of VIVITROL® were $41.2 million for fiscal 2012 ...

6 High-Growth Biotech Stocks Analysts Rate As Buys - Seekingalpha.com

Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity.